AxoGen (NASDAQ:AXGN) Stock Breaks Above Two Hundred Day Moving Average – Here’s Why

AxoGen, Inc. (NASDAQ:AXGN)’s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $39.28 and traded as high as $49.97. AxoGen shares last traded at $49.25, with a volume of 9,288,508 shares traded.

Key Headlines Impacting AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Strong Q3 execution and higher guidance: AxoGen reported 26% revenue growth and 45% adjusted EBITDA growth for the third quarter of 2026. Management maintained a target of at least $290 million in 2026 sales and expects gross margin of 73% or higher, reinforcing the company’s growth and operating-leverage story. AxoGen Third-Quarter Earnings Results
• Positive Sentiment: Analysts raised their targets: Canaccord Genuity increased its price target to $60 from $55 and maintained a Buy rating. Truist also raised its target to $60 from $53, while Wells Fargo increased its target to $56 from $48 and kept an Overweight rating. HC Wainwright lifted its target to $56 from $53 and retained a Buy rating. These revisions indicate improving confidence in AxoGen’s earnings outlook. Truist AxoGen Price Target Update
• Positive Sentiment: BioCircuit acquisition expands the opportunity: An investment analysis characterized AxoGen as evolving toward a leading procedural platform in peripheral nerve repair. The planned $200 million BioCircuit, or NerveTape, acquisition is intended to reduce technical barriers for surgeons, broaden the addressable market and be accretive at an estimated 5.9 times 2027 sales. AxoGen Taking the Friction Out of Nerve Repair
• Neutral Sentiment: Valuation remains an investor debate: Coverage is focused on whether AXGN’s growth prospects justify its elevated valuation after its substantial advance. The stock’s performance relative to other medical companies may attract momentum investors, but also raises the risk that much of the near-term optimism is already reflected in the share price. Does AxoGen Have More Upside?
• Negative Sentiment: Profitability and execution risks remain: Despite improving adjusted EBITDA, AxoGen continues to report negative net income and analysts expect a full-year loss. Investors must also weigh acquisition integration, dilution and the company’s premium valuation against the possibility of slower growth.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Wells Fargo & Company boosted their target price on AxoGen from $48.00 to $56.00 and gave the company an “overweight” rating in a report on Thursday. Morgan Stanley downgraded AxoGen to a “hold” rating in a report on Tuesday, September 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price objective on shares of AxoGen in a research report on Wednesday. Barclays lifted their price objective on shares of AxoGen from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, HC Wainwright boosted their price objective on shares of AxoGen from $53.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $57.92.

AxoGen Price Performance

The stock has a fifty day moving average of $42.86 and a two-hundred day moving average of $39.45. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -75.95 and a beta of 1.17. The company has a quick ratio of 5.04, a current ratio of 12.02 and a debt-to-equity ratio of 0.04.

AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. The company had revenue of $75.83 million during the quarter, compared to the consensus estimate of $73.45 million. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. On average, equities research analysts anticipate that AxoGen, Inc. will post -0.44 earnings per share for the current year.

Insider Activity at AxoGen

In related news, Director Kathy Weiler sold 14,150 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $45.30, for a total value of $640,995.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Wendell sold 13,353 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total transaction of $646,552.26. Following the sale, the director directly owned 107,976 shares in the company, valued at approximately $5,228,197.92. This represents a 11.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 98,503 shares of company stock worth $4,656,947. 2.44% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of AxoGen during the 2nd quarter worth $204,123,000. Artemis Investment Management LLP boosted its position in shares of AxoGen by 27.5% in the 3rd quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock worth $74,659,000 after buying an additional 384,200 shares in the last quarter. Wellington Management Group LLP grew its stake in AxoGen by 44.3% in the 2nd quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider’s stock valued at $64,280,000 after acquiring an additional 427,089 shares during the last quarter. Bamco Inc. NY acquired a new stake in AxoGen in the 2nd quarter valued at about $34,190,000. Finally, TimesSquare Capital Management LLC acquired a new stake in AxoGen in the 2nd quarter valued at about $31,863,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.